{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:12:30Z","timestamp":1788883950503,"version":"build-2803163510"},"reference-count":16,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>We examined the impact of acarbose, an \u03b1-glucosidase inhibitor, on incident diabetes and regression to normoglycemia in 6,522 Acarbose Cardiovascular Evaluation (ACE) trial participants in China who had impaired glucose tolerance (IGT) and coronary heart disease (CHD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Participants were randomly assigned to acarbose or placebo and followed with four monthly fasting plasma glucose (FPG) tests and annual oral glucose tolerance tests. Incident diabetes was defined as two successive diagnostic FPG levels \u22657 mmol\/L or 2-h plasma glucose (PG) levels \u226511.1 mmol\/L while taking study medication or a masked adjudicated confirmation of this diagnosis. Regression to normoglycemia was defined as FPG &amp;lt;6.1 mmol\/L and 2-h PG &amp;lt;7.8 mmol\/L. Intention-to-treat and on-treatment analyses were conducted using Poisson regression models, overall and for subgroups (age, sex, CHD type, HbA1c, FPG, 2-h PG, BMI, estimated glomerular filtration rate, for IGT alone, for IGT + impaired fasting glucose, and for use of thiazides, ACE inhibitors [ACEis]\/angiotensin receptor blockers [ARBs], \u03b2-blockers, calcium channel blockers, or statins).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Incident diabetes was less frequent with acarbose compared with placebo (3.2 and 3.8 per 100 person-years, respectively; rate ratio 0.82 [95% CI 0.71, 0.94], P = 0.005), with no evidence of differential effects within the predefined subgroups after accounting for multiple testing. Regression to normoglycemia occurred more frequently in those randomized to acarbose compared with placebo (16.3 and 14.1 per 100 person-years, respectively; 1.16 [1.08, 1.25], P &amp;lt; 0.0001). This effect was greater in participants not taking an ACEi or ARB (1.36 [1.21, 1.53], Pinteraction = 0.0006). The likelihood of remaining in normoglycemic regression did not differ between the acarbose and placebo groups (P = 0.41).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Acarbose reduced the incidence of diabetes and promoted regression to normoglycemia in Chinese people with IGT and CHD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc19-2046","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T23:15:43Z","timestamp":1594250143000},"page":"2242-2247","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":28,"title":["Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial"],"prefix":"10.2337","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct00829660","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-2836","authenticated-orcid":false,"given":"Hertzel C.","family":"Gerstein","sequence":"first","affiliation":[{"name":"Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-8550","authenticated-orcid":false,"given":"Ruth L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.B.","family":"Scott","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishi","family":"Xu","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Tuomilehto","sequence":"additional","affiliation":[{"name":"Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland"},{"name":"Department of Public Health, University of Helsinki, Helsinki, Finland"},{"name":"Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-4697","authenticated-orcid":false,"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-874X","authenticated-orcid":false,"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"2022031223522083000_B1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/dc16-0873","article-title":"Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a diabetes care editors\u2019 expert forum","volume":"39","author":"Cefalu","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031223522083000_B2","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.2337\/dc18-S005","article-title":"5. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031223522083000_B3","doi-asserted-by":"crossref","first-page":"i5953","DOI":"10.1136\/bmj.i5953","article-title":"Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis","volume":"355","author":"Huang","year":"2016","journal-title":"BMJ"},{"key":"2022031223522083000_B4","doi-asserted-by":"crossref","first-page":"e0142045","DOI":"10.1371\/journal.pone.0142045","article-title":"Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study","volume":"10","author":"George","year":"2015","journal-title":"PLoS One"},{"key":"2022031223522083000_B5","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"2022031223522083000_B6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"2022031223522083000_B7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","article-title":"Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies","volume":"25","author":"Hanefeld","year":"2004","journal-title":"Eur Heart J"},{"key":"2022031223522083000_B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00125-003-1318-y","article-title":"Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data","volume":"47","author":"Kaiser","year":"2004","journal-title":"Diabetologia"},{"key":"2022031223522083000_B9","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1210\/jc.2018-00040","article-title":"Cardiovascular benefits of acarbose vs sulfonylureas in patients with type 2 diabetes treated with metformin","volume":"103","author":"Hsu","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223522083000_B10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031223522083000_B11","first-page":"23\u201329.e2","article-title":"Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial","volume-title":"Am Heart J","author":"Holman","year":"2014"},{"key":"2022031223522083000_B12","first-page":"CD012661","article-title":"Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia","volume":"10","author":"Richter","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031223522083000_B13","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ehj.2004.07.027","article-title":"The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart","volume":"25","author":"Bartnik","year":"2004","journal-title":"Eur Heart J"},{"key":"2022031223522083000_B14","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1093\/eurheartj\/ehl207","article-title":"The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey","volume":"27","author":"Hu","year":"2006","journal-title":"Eur Heart J"},{"key":"2022031223522083000_B15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031223522083000_B16","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"McMurray","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc19-2046","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/9\/2242\/630570\/dc192046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/9\/2242\/630570\/dc192046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:48:48Z","timestamp":1647143328000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/9\/2242\/35831\/Impact-of-Acarbose-on-Incident-Diabetes-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,7,8]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-2046","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]}}}